Licensing status

Publication and contact information

Infectious disease

Viral infection

IL-29 (IFNL1)

Studies in patient samples suggest IL-29 could help treat the viral infections that frequently accompany atopic dermatitis. In skin biopsies, IL-29 expression was associated with the production of antiviral proteins. In a 3D model of human epidermis and in explanted skin biopsies from healthy individuals, IL-29 increased expression of antiviral proteins compared with no IL-29. Next steps could include testing IL-29 in models of atopic dermatitis.
Bristol-Myers Squibb Co. has recombinant IL-29 in Phase III testing to treat HCV.

SciBX 6(43); doi:10.1038/scibx.2013.1230
Published online Nov. 7, 2013

Patent and licensing status unavailable

Wolk, K. et al. Sci. Transl. Med.; published online Sept. 25, 2013; doi:10.1126/scitranslmed.3006245
Contact: Robert Sabat, Charité-University Hospital Berlin,
Berlin, Germany
Contact: Kerstin Wolk, same affiliation as above